Announcements

Axsome Therapeutics, Inc. filed a current report on August 10, 2026, announcing its financial results for the three months ended June 30, 2026, and providing an update on company operations.

Shoulder Innovations, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 10, 2026, disclosing the appointment of Jon Osborne as Chief Commercial Officer via a press release furnished under Regulation FD.

News Corporation filed a Form 8-K on August 10, 2026, reporting the attachment of share repurchase transaction disclosures provided to the Australian Securities Exchange on dates noted in the accompanying exhibits.

Sionna Therapeutics, Inc. filed a Form 8-K on August 10, 2026, announcing topline data from its PreciSION CF Phase 2a proof-of-concept trial of SION-719 and its Phase 1 trial of SION-451-based proprietary dual combinations, along with a corporate update on next steps.

Tenax Therapeutics, Inc. filed a current report on Form 8-K on August 10, 2026, announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF, along with a conference call and live webcast held the same day.

Surgery Partners, Inc. filed a current report on August 10, 2026, announcing financial results for the three and six months ended June 30, 2026, along with a scheduled investor conference call for the same date.

Liberty Media Corporation filed an 8-K with the U.S. Securities and Exchange Commission on August 10, 2026, disclosing a proposed offering of $600 million aggregate principal amount of convertible senior notes due 2032.